HISTORY

2021

July

  • Entering into MOU to develop RMAT (Regenerative Medicine Advanced Treatment) programs in collaborations with ALBIOTEK, Inc.

 

  • Entering into MOU with NFC, Inc.

June

  • Entering into MOU to develop RMAT (Regenerative Medicine Advanced Treatment) programs in collaborations with Pusan National University Hospital

May

  • Entering into MOU to form a business relationship on areas of mutual interest in the field of cell therapy and iPSC Biobanking with Allele Biotechnology & Pharmaceuticals

 

  • Entering into MOU with Hicell Tech, Inc.

April

  • Becoming a regular member of KoBIA (Korea Biomedicine Industry Association)

 

  • A Korean patent ‘Novel musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell(KR10-2241185)’ has been registered.

2020

November

  • Signed a contract with Femtobiomed to commercialization R&D and evaluation.

October

  • A Japanese patent ‘Novel musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell(JP6786145)’ has been registered.

May

  • A Korean patent ‘Novel musculoskeletal stem cell(KR10-2118522)’ has been registered.

March

  • GMP Certification

 

  • A U.S. patent ‘Novel musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell(US10,576,106)’  has been registered.

2019

November

  • Complete the registration of a manufacturing factory

September

  • Construction of GMP in Cellatoz Therapeutics

 

  • Relocating the headquarter and the research center

May

  • Entering into MOU to develop technology of manufacturing automation with Curiosis, Inc.
KakaoTalk_20190510_1807391991

February

  • Entering into MOU to develop RMAT (Regenerative Medicine Advanced Treatment) programs in collaborations with Seoul National University Bundang Hospital

January

  • Signed a contract with governor of Chungcheongbuk-do to move into the
    Advanced Medical Complex in Oh-song

2018

October

  • Entering into MOU to develop RMAT (Regenerative Medicine Advanced Treatment) programs in collaborations with Ewha Woman’s University Medical Center

September

  • Entering into Exclusive License Agreements with Ewha Woman’s University on patents relating to methods of differentiating neuro-muscular tissue cells from Tonsil-mesenchymal stem cells (T-MSC) for the worldwide territory.

July

  • Entering into Technology & Patent Transfer Agreement with Chonbuk National University on a research program related to Musculoskeletal Stem Cells (MSSC)
  • Becoming a regular member of CARM (Council for Advanced Regenerative Medicine)

June

  • Inviting seed investment from Venture Capitals (KRW 15B)

February

  • Opening head office & research laboratory within Institut Pasteur Korea
  • Designated as a Venture Company accredited by KIBO (Korea Technology Finance Corporation)

January

  • Obtaining a certification of Company-owned Research Laboratory from KOITA (Korea Industrial Technology Association)

2017

November

  • Cellatoz Therapeutics, Inc. was selected as one of five incubating startup biotechs in BIO Core Facility Program operated by Institut Pasteur Korea and funded by MSIT (Ministry of Science and ICT)

August

  • Cellatoz Therapeutics, Inc. established.